CRESCENDO (Compliance: Role Emerges for Success in CML: Evaluation aND Optimisation): A Prospective, Multi-center, Phase IV Study to Assess the Compliance in Patients With Philadelphia Chromosome-positive (Ph+) and/or BCR-ABL Positive Chronic Myelogenous Leukaemia (CML) Under Long-term Imatinib Therapy.
Phase of Trial: Phase IV
Latest Information Update: 16 Sep 2014
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms CRESCENDO
- 26 Mar 2014 According to European Clinical Trials Database, status changed from active, no longer recruiting to completed.
- 13 Mar 2013 Planned end date changed from 1 Oct 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 13 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.